Service
Starting out from your targets or your molecules, we design and select the best drug candidates
IDDS (Integrated Drug Discovery Services) Proof of concept - Pharmacology DMPK Bioanalysis Biobanking Translational Biomarkers Biodecontamination / biosafetyPartnership
Use our development programs at a very early stage by entering into a long-term strategic partnership
Kinase inhibitor development programs Technology PartnershipLicensing
License technologies, drug candidates and radiotracers from Oncodesign’s portfolio
Kinase inhibitors in oncology, CNS and inflammation TechnologiesTechnologies
The power and selectivity of Nanocyclix® molecules applied to the entire kinome. Learn More
Oncodesign News
[Congress] J.P. Morgan Healthcare Conference & Biotech Showcase – 13-16 January – San Francisco
[Congress] J.P. Morgan Healthcare Conference & Biotech Showcase – 13-16 January – San Francisco
[Congress] FOP Drug Development Forum (DDF) - 13-14 November - Orlando, FL - USA
[Congress] FOP Drug Development Forum (DDF) - 13-14 November - Orlando, FL - USA. A new generation of kinase inhibitors at for therapeutic innovation.
Word from the Chairman
Since our April 2014 IPO, we have accelerated our development and have become an international biopharma company specialized in precision medicine pursuing ambitious development objectives underpinned by acquisition-led growth and investments in innovative therapeutic research programs.
Learn More
Careers
Oncodesign’s mission is to discover innovative new therapies effective against cancer and serious illnesses with unmet medical needs.
Oncodesign has opted to take the time to build up all the dimensions of its organization—scientific, technical, business, starting with the most crucial one, the human dimension.
Our values Job offers/work-study arrangements Internship available Spontaneous applicationsContact Us
Sales team
If you have any questions, please contact the member of our sales team responsible for your geographical region, and we will get back to you as swiftly as we can.